IMPORTANT SAFETY INFORMATIONPRESCRIBING INFORMATION

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.

Proactive evaluation, regular monitoring, and dose modification may help address the severity of mucositis1

  • Prior to administering any dose, mucositis should be ≤Grade 1
  • Treatment with FOLOTYN may cause mucositis. If ≥Grade 2 mucositis is observed, dose should be omitted and/or reduced. Severity of mucositis should be monitored at baseline and weekly

Dose modifications for mucositis1

Dose modifications for Grade 2-4 mucositis

*Per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE, Version 3.0)

Train your staff
and
educate your patients
to proactively evaluate and regularly monitor
for mucositis

References:

  • FOLOTYN Prescribing Information. Allos Therapeutics, Inc. 2012.